Abstract

Review Article

A Concise Review - An Analytical Method Development and Validation of Vildagliptin

Pritam Jain*, Ronak Patil, Yash Jaiswal, Aditya Patil and Nitin G Haswani

Published: 14 July, 2025 | Volume 9 - Issue 1 | Pages: 021-030

Vildagliptin is an orally active, potent, and selective Dipeptidyl Peptidase-4 (DPP-4) inhibitor, shown to be effective and well tolerated in patients with Type 2 Diabetes Mellitus (T2DM) as either monotherapy or in combination with other anti-diabetic agents. Vildagliptin is used to treat type 2 diabetes mellitus, typically in conjunction with diet and exercise. Vildagliptin is usually administered orally, with a common dosing regimen of 50 mg twice daily. It can be taken with or without food; however, it is important to take it consistently at the same time each day for optimal effectiveness.
This study focuses on the most recent advancements in analytical methods for determining the presence of Vildagliptin in different biological media, such as human plasma and urine, as well as in bulk and commercial dose forms. The following analytical techniques will be fully investigated in this paper: High-pressure Liquid Chromatography (HPLC), High Efficiency Thin Layer Chromatography (HPTLC), liquid chromatography coupled to a tandem mass spectrometry system (LC-MS), and electrophoresis. These techniques include several parameters, such as the following: matrix, dynamic phase composition, permanent phase RF value for sensing frequency, retention duration, DL, carrier gas, flow rate, capillary wavelength, separation voltage, temperature, and pressure.

Read Full Article HTML DOI: 10.29328/journal.apps.1001067 Cite this Article Read Full Article PDF

Keywords:

Vildagliptin; HPLC; LC-MS/MS; HPTLC; LC-MS; Spectrophotometry; Electroanalytical method; Electrophoresis

References

  1. He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012;51:147-62. Available from: https://doi.org/10.2165/11598080-000000000-00000
  2. Henness S, Keam SJ. Vildagliptin. Drugs. 2006 Oct;66:1989-2001. Available from: https://doi.org/10.2165/00003495-200666150-00007
  3. Lauster CD, McKaveney TP, Muench SV. Vildagliptin: a novel oral therapy for type 2 diabetes mellitus. Am J Health Syst Pharm. 2007 Jun 15;64(12):1265-73. Available from: https://doi.org/10.2146/ajhp060564
  4. Vildagliptin package insert. Available from: https://www.geneesmiddeleninformatiebank.nl/pars/h124950.pdf
  5. Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2008 Nov;68:2387-409. Available from: https://doi.org/10.2165/0003495-200868160-00009
  6. He H, Tran P, Yin H, Smith H, Batard Y, Wang L, et al. Absorption, metabolism, and excretion of [14C] vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos. 2009 Mar 1;37(3):536-44. Available from: https://doi.org/10.1124/dmd.108.023010
  7. Vildagliptin: Uses, Interactions, Mechanism of Action – DrugBank.. Available from: https://go.drugbank.com/drugs/DB04876
  8. Alok Pote, Santhanam Ravisankar, Ganesh Sangle, Sunil Agarwal, Mohan Patil, Nitin Deshmukh, et al.Clinical pharmacokinetics and pharmacodynamics of vildagliptin 50 mg sustained release tablet formulation in healthy Indian males after single and multiple-dose. Int J Res Med Sci. 2021;9:510-517.Available from: https://doi.org/10.18203/2320-6012.ijrms20210433
  9. He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2007;46(7):577-88. Available from: https://doi.org/10.2165/00003088-200746070-00003
  10. Serra YL. Pharmacokinetics and Pharmacodynamics of Vildagliptin in Patients with Type 2 Diabetes Mellitus. Semantics Scholar. Available from: https://www.semanticscholar.org/paper/Pharmacokinetics-and-Pharmacodynamics-of-Vildagliptin-Serra/
  11. Boovizhikannan T, Palanirajan VK. RP-HPLC determination of vildagliptin in pure and in tablet formulation. J Pharm Res. 2013;7(1):113-6. Available from: https://doi.org/10.1016/j.jopr.2013.01.001
  12. Kashid AM, Ghorpade DA, Toranmal PP, Dhawale SC. Development and validation of a reversed-phase HPLC method for the determination of vildagliptin using an experimental design. J Anal Chem. 2015;70:510-5. Available from: http://dx.doi.org/10.1134/S1061934815040061
  13. Sujeetkumar A, Sandhya A, Patil PR, Akshata J, Archana C. Development of RP-HPLC Method for Vildagliptin in Pharmaceutical Dosage Form. Int J Pharm Sci Rev Res. 2023;78(1):36-40. Article No. 06. Available from: https://globalresearchonline.net/ijpsrr/v78-1/06.pdf
  14. Malakar A, Bokshi B, Nasrin D. Development and validation of RP-HPLC method for estimation of vildagliptin from tablet dosage form. Int J Pharm Life Sci. 2012;1(1). Available from: https://doi.org/10.3329/ijpls.v1i1.12947
  15. Dhale C, Janhavi RR. Stability Indicating HPLC MS method for determination of degradation products in Vildagliptin. J Anal Bioanal Tech. 2019;10:1-5. Available from: https://www.researchgate.net/publication/354066375_Stability_Indicating_HPLC_MS_Method_for_Determination_of_Degradation_Products_in_Vildagliptin
  16. Jayaprakash R, Natesan SK, Lalitha K. Stability indicating RP-HPLC method development and validation for the simultaneous determination of vildagliptin and metformin in pharmaceutical dosage form. Int J Pharm Pharm Sci. 2017;9(3):150-7. Available from: https://core.ac.uk/download/pdf/482240668.pdf
  17. Raosaheb JR, Dabhade MP, Vikram KS, Sanjay SV, Chand SW. RP-HPLC method development and validation of vildagliptin in bulk and dosage form. World J Pharm Pharm Sci. 2017;6(9):1161-76. Available from: http://dx.doi.org/10.20959/wjpps20179-9980
  18. Dayyih WA, Hamad M, Mallah E, Dayyih AA, Awad R, Zakaria Z, et al. METHOD Development and Validation of Vildagliptin and Metformin HCl in Pharmaceutical Dosage form by Reversed Phase-High Performance Liquid Chromatography (RP-HPLC). Int J Pharm Sci Res. 2018;9(7):2965-72. Available from: https://www.researchgate.net/publication/328407528_Method_Development_And_Validation_of_Vildagliptin_and_Metformin_HCL_in_Pharmaceutical_Dosage_Form_by_Reversed_Phase-High_Performance_Liquid_Chromatography_RP-HPLC
  19. Rao KH, Rao AL, Sekhar KB. DEVELOPMENT AND VALIDATION OF HPLC METHOD FOR THE ESTIMATION OF VILDAGLIPTIN IN PHARMACEUTICAL DOSAGE FORM. Int J Pharm Chem Biol Sci. 2014;4(2):361-366. Available from: https://www.ijpcbs.com/articles/development-and-validation-of-hplc-method-for-theestimation-of-vildagliptin-in-pharmaceutical-dosage-form.pdf
  20. Deshmukh SB, Jadhao UT, Patil JA, Thoke ST. Analytical method development and validation of vildagliptin in bulk drug and its pharmaceutical dosage form by RP-HPLC. Int J Res Publ Rev. 2024:3350-3357. Available from: https://ijrpr.com/uploads/V5ISSUE4/IJRPR25059.pdf
  21. Barden AT, Piccoli BL, Volpato NM, Steppe M. Second-order derivative UV spectrophotometric and RP-HPLC methods for the analysis of vildagliptin and application for dissolution study. Drug Anal Res. 2018;2(1):46-53. Available from: http://dx.doi.org/10.22456/2527-2616.86511
  22. Al-Qudah E, Arar S, Sweidan K. Forced degradation studies of vildagliptin raw material alone and in the presence of excipients using HPLC-UV analysis. J Excipients Food Chem. 2020;11(2):29-41. Available from: https://jefc.scholasticahq.com/article/13503-forced-degradation-studies-of-vildagliptin-raw-material-alone-and-in-the-presence-of-excipients-using-hplc-uv-analysis
  23. Barden AT, Salamon B, Schapoval EE, Steppe M. Stability-indicating RP-LC method for the determination of vildagliptin and mass spectrometry detection for a main degradation product. J Chromatogr Sci. 2012;50(5):426-32. Available from: https://doi.org/10.1093/chromsci/bms024
  24. Chaphekar MM, Hamrapurkar PD. Development and validation of RP-HPLC assay method for vildagliptin using QbD approach and its application to forced degradation studies. Int J Pharm Sci Drug Res. 2016;8:157-65. Available from: http://dx.doi.org/10.25004/IJPSDR.2016.080306
  25. Mohammad MA, Elkady EF, Fouad MA. Development and validation of a reversed-phase column liquid chromatographic method for the simultaneous determination of two novel gliptins in their binary mixtures with metformin. Eur J Chem. 2012;3(2):152-5. Available from: https://doi.org/10.5155/eurjchem.3.2.152-155.570
  26. Satheeshkumar N, Pradeepkumar M, Shanthikumar S, Rao VJ. Development of a validated stability-indicating assay method for simultaneous estimation of metformin hydrochloride and vildagliptin by RP-HPLC. Drug Res (Stuttg). 2014;64(03):124-9. Available from: https://doi.org/10.1055/s-0033-1354373
  27. Galande VV, Kolhe MH, Khatal AR, Bhor RJ, Gawali PS, Bhalerao PS, et al. Stability Indicating Method Development and Validation of Vildagliptin and Dapagliflozin in Bulk and Marketed Formulation by UHPLC Method. Int J Pharm Investig. 2024;14(3):1599-1603. Available from: http://dx.doi.org/10.25258/ijddt.14.3.49
  28. Sultana R, Bachar SC, Rahman F. Development and validation of stability indicating assay method of vildagliptin in bulk and tablet dosage form by RP-HPLC. Int J Pharm Life Sci. 2013;4(4):2530-4. Available from: https://www.researchgate.net/publication/263085943_Development_and_validation_of_stability_indicating_assay_method_of_vildagliptin_in_bulk_and_tablet_dosage_form_by_RP-HPLC
  29. Sultana S, Kumar U, Hossain MS, Lira DN, Rouf AS. QbD approach for the development and validation of RP-UHPLC method for quantitation of vildagliptin. Dhaka Univ J Pharm Sci. 2017;16(1):107-17. Available from: https://doi.org/10.3329/dujps.v16i1.33388
  30. Satpathy PR, Goud VM, Bhagya B, Sharma JV, Shyamala N. Development and validation of an RP-HPLC method for the assay of vildagliptin. World J Pharm Pharm Sci. 2014;3(2):2303-10. Available from: https://www.researchgate.net/profile/Mohan-Goud/publication/260788523_Development_and_validation_of_RP-HPLC_method_for_the_assay_of_vildagliptin/links/0deec53234bf790563000000/Development-and-validation-of-RP-HPLC-method-for-the-assay-of-vildagliptin.pdf
  31. Bendale AR, Singh RP, Vidyasagar G. Development and validation of stability-indicating HPTLC method for determination of vildagliptin and metformin hydrochloride in the pharmaceutical dosage forms. Int J Appl Pharm. 2018;10(1):36-45. Available from: http://dx.doi.org/10.22159/ijap.2018v10i1.20555
  32. Al Bratty M, Alhazmi HA, Javed SA, Lalitha KG, Asmari M, Wölker J, et al. Development and validation of–LC-MS/MS method for simultaneous determination of metformin and four gliptins in human plasma. Chromatographia. 2017;80:891-9. Available from: https://link.springer.com/article/10.1007/s10337-017-3288-0
  33. Sakthimanigandan K, Ganesh M, Kanthikiran V, Sivakumar T, Jang H. Liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the determination of Vildagliptin in rat plasma. Acta Chromatogr. 2015;27(2):295-307. Available from: https://doi.org/10.1556/achrom.27.2015.2.7
  34. Mohite P, Bhusal R, Khandre Y, Pandhare R, Pawar A. A new gas chromatographic method for quantification of Metformin hydrochloride and Vildagliptin in bulk and pharmaceutical dosage form: development and validation. Future J Pharm Sci. 2024;10(1):62. Available from: https://link.springer.com/article/10.1186/s43094-024-00635-z
  35. Uçaktürk E. Development of Sensitive and Specific Analysis of Vildagliptin in Pharmaceutical Formulation by Gas Chromatography‐Mass Spectrometry. J Anal Methods Chem. 2015;2015(1):707414. Available from: https://doi.org/10.1155/2015/707414
  36. Barden AT, Piccoli BL, Volpato NM, Schapoval EE, Steppe M. Capillary zone electrophoresis for determination of vildagliptin (a DPP-4 inhibitor) in pharmaceutical formulation and comparative study with HPLC. Pharmazie. 2014;69(2):86-91. Available from: https://doi.org/10.1691/ph.2014.3123
  37. Attimarad M, Nagaraja SH, Aldhubiab BE, Nair AB, Venugopala KN. Determination of vildagliptin in rat plasma by capillary electrophoresis tandem mass spectrometry: Its application to pharmacokinetic study. Indian J Pharma Edu Res. 2017;51:636-43. Available from: https://pdfs.semanticscholar.org/2168/574154f236935ead1937ff97872c7001746e.pdf
  38. Banik S, Karmakar P, Miah MA. Development and validation of a UV-spectrophotometric method for the determination of vildagliptin and linagliptin in bulk and pharmaceutical dosage forms. Bangladesh Pharm J. 2015;18(2):163-8. Available from: https://doi.org/10.3329/bpj.v18i2.24316
  39. Gundala U, Bhuvanagiri CS, Nayakanti D. Simultaneous estimation of vildagliptin and metformin in bulk and pharmaceutical formulations by UV spectrophotometry. Am J PharmTech Res. 2013;3(1):338-45. Available from: https://www.researchgate.net/publication/250612476_Simultaneous_Estimation_of_Vildagliptin_and_Metformin_in_Bulk_and_Pharmaceutical_Formulations_by_UV_Spectrophotometry
  40. Mane SV, Khan MA. Development of UV-Visible spectrophotometric method for the estimation of vildagliptin in different media. J Pharm Biol Sci. 2022;10(2):83-7. Available from: http://dx.doi.org/10.18231/j.jpbs.2022.016
  41. Tekkeli SE, Bahadori FA. Development and validation of spectrophotometric methods for the determination and spectroscopic characterization of vildagliptin using II-acceptors in pharmaceutical preparations. J Chil Chem Soc. 2014;59(4):2705-9. Available from: http://dx.doi.org/10.4067/S0717-97072014000400016

Figures:

Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?